EYPT EyePoint Pharmaceuticals
- 11.590
- -0.550-4.53%
EyePoint Pharmaceuticals News
HC Wainwright & Co. : The EyePoint Pharmaceuticals (EYPT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $30.00.
EyePoint Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $30
EyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and Trials
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Positive Duravyu Trial Insights and Future Prospects
Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating
EyePoint Pharmaceuticals Analyst Ratings
EyePoint Pharmaceuticals Analyst Ratings
Maintaining Buy Rating on EyePoint Pharmaceuticals: Strong Prospects in WAMD Market Despite NPDR Study Setback
Bullish Buy Rating Reaffirmed for EyePoint Pharmaceuticals With a $39 Price Target
Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know
EyePoint Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Oxford BioMedica (OXBDF), EyePoint Pharmaceuticals (EYPT)
EyePoint Pharmaceuticals: Strategic Leadership Appointment and Positive Developments Bolster Buy Rating
Mizuho Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $39
EyePoint Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and EyePoint Pharmaceuticals (EYPT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)
EyePoint Pharmaceuticals Earns Buy Rating Following Promising EYP-1901 Clinical Trial Results
Analysis
Price Target
No Data
